Send Message
View as an RSS Feed
  • Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept  [View article]
    about incy , there is a rumor that gild will buy them
    what is your take?
    Nomura analyst M. Ian Somaiya said he sees Incyte (NASDAQ: INCY) as the company's most likely takeout target based on Jakafi’s ~$3bn peak sales potential in MF, PV, and solid tumors and 18-28% royalty on baricitinib sales that could reach $2.5bn in RA alone "
    Sep 1, 2015. 08:53 AM | Likes Like |Link to Comment
  • 4 Reasons To Be Bullish On Exelixis In The Near Term  [View article]
    why Pre-market ~ -20 % ?
    Mar 26, 2014. 09:12 AM | 1 Like Like |Link to Comment
  • FDA's Rejection Of Aveo's Tivozanib Defies Logic  [View article]
    there was a patient's petition
    Aug 15, 2013. 09:59 AM | Likes Like |Link to Comment
  • AVEO: Here's Looking At You, FDA  [View article]
    How come none of the blogers and research companies talking about aveo better safety profile never show table 13 ?!
    May 5, 2013. 08:26 AM | Likes Like |Link to Comment
  • Investing In Cocoa: The Definitive Guide  [View article]
    Hi Carolyn
    you wrote "the price of cocoa is now at its highest level since its transition from delicacy to every day treat in the 80′s."
    so why NIB is about 30 when he saw 50 two years ago

    Feb 11, 2013. 11:22 AM | Likes Like |Link to Comment
  • BioPharma Stocks On The Move Today And For The Rest Of The Week  [View article]
    Hello Scott
    why acad needs to conduct another Phase III trial?
    cant the fda look into 020 results, why repeating the same tests once again?
    Nov 28, 2012. 12:23 PM | Likes Like |Link to Comment
  • AVEO Pharmaceuticals: Attractive Following Recent De-Risking Events  [View article]
    is aveo still a buy to your opinion? or nexavar change it?

    Oct 29, 2012. 06:27 AM | Likes Like |Link to Comment
1 Like